Exscientia strengthens drug design capability with key appointments

Building on three commercial agreements ex scientia reports two key hires to head up expanded teams in molecular and chemo informatics. Willem Van Hoorn comes to ex scientia following over a decade at Pfizer focusing on computational techniques for HTS triage and combinatorial library design. Adrian Schreyer comes straight from the University of Cambridge where he focused his research on computational approaches to drug discovery. Andrew Hopkins, CEO said, ā€œIā€™m delighted to welcome both a former colleague and a new talent to ex scientia. Their combined expertise will allow us to expand our capabilities to meet key commercial priorities.ā€